Human growth hormone subcutaneous administration

Figure 13.8. Effects of route and sustained release formulation on the time course of human growth hormone concentration in plasma. Shown is the average time course of human growth hormone (hGH) in plasma after intravenous (0.02mg/kg) and subcutaneous (0.1 mg/kg) administration in humans. Arrows indicate weekly subcutaneous dosing of hGH in solution. A single dose of the same protein formulated in polylactide-co-glycolide (PLG) microspheres (0.75 mg/kg) given subcutaneously sustains human growth hormone levels in plasma for at least one month.

Verhagen, A. Ebels, J.T. Dogterom, A.A. Jonkman, J.H. Pharmacokinetics and pharmacodynamics of a single dose of recombinant human growth hormone after subcutaneous administration by jet-injection comparison with conventional needle-injection. Eur. J. Clin. Pharmacol. 1995, 49 (1-2), 69-72. 

Fig. 2 The influence of Sandostatin LAR biodegradable depot formulation on the mean plasma growth hormone concentrations in humans. Plasma concentrations are shown over a 24 hour period 28 days after administration of a second monthly 20mg dose of Sandostatin LAR, . For comparison, plasma concentrations are provided for untreated controls, , and for patients receiving multiple daily subcutaneous octreotide injections, A. (From Refs. ° ° l)...

---